Less invasive surgical implant strategy and right heart failure after LVAD implantation

Diyar Saeed; Rahatullah Muslem; Moniba Rasheed; Kadir Caliskan; Nikolaos Kalampokas; Firat Sipahi; Artur Lichtenberg; Khalil Jawad; Michael Borger; Simone Huhn; Rebecca Cogswell; Ranjit John; Jessica Schultz; Hirak Shah; Steven Hsu; Nisha A. Gilotra; Paul J. Scheel; Brett Tomashitis; Milad El Hajj; Lucian Lozonschi; Brian A. Houston; Ryan J. Tedford

doi:10.1016/j.healun.2021.01.005

Less invasive surgical implant strategy and right heart failure after LVAD implantation

Diyar Saeed, Rahatullah Muslem, Moniba Rasheed, Kadir Caliskan, Nikolaos Kalampokas, Firat Sipahi, Artur Lichtenberg, Khalil Jawad, Michael Borger, Simone Huhn, Rebecca Cogswell, Ranjit John, Jessica Schultz, Hirak Shah, Steven Hsu, Nisha A. Gilotra, Paul J. Scheel, Brett Tomashitis, Milad El Hajj, Lucian LozonschiBrian A. Houston, Ryan J. Tedford

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

BACKGROUND: Conventional median sternotomy (CMS) is still the standard technique utilized to implant left ventricular assist devices (LVADs). Recent studies suggest that less invasive surgery (LIS) may be beneficial; however, robust data on differences in right heart failure (RHF) are lacking. This study aimed to determine the impact of LIS compared with that of CMS on RHF outcomes after LVAD implantation. METHODS: An international multicenter retrospective cohort study was conducted across 5 centers. Patients were grouped according to their implantation technique (LIS vs CMS). Only centrifugal devices were included. RHF was defined as severe or severe acute RHF according to the 2013 Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definition. Logistic multivariate regression and propensity score‒matched analyses were performed to account for confounding. RESULTS: Overall, 427 implantations occurred during the study period, with 305 patients implanted using CMS and 122 using LIS. Pre-operative extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump (IABP) use was more common in the CMS group; off-pump implantation was more common in the LIS group. Other pre-implant variables, including age, creatinine, hemodynamics, and tricuspid regurgitation, did not differ between the 2 groups. Post-operative RHF was less common in the patients who underwent LIS than in those who underwent CMS as was post-operative right ventricular assist device (RVAD) use. LIS remained associated with less RHF in the multivariate analysis. After propensity score matching conditional for age, sex, INTERMACS profile, ECMO, and IABP use in a ratio of 2:1 (CMS to LIS), RHF (29.9% vs 18.6%, p = 0.001) and the need for post-operative RVAD (18.6% vs 8.2%; p = 0.009) remained more common in the CMS group than in the LIS group. There were no significant differences in survival up to 1 year between the groups. CONCLUSIONS: LIS may be associated with less RHF after LVAD implantation compared with CMS. Despite the possible reduction in RHF, there was no difference in 1-year survival. LIS is an alternative to traditional CMS.

Original language	English (US)
Pages (from-to)	289-297
Number of pages	9
Journal	Journal of Heart and Lung Transplantation
Volume	40
Issue number	4
DOIs	https://doi.org/10.1016/j.healun.2021.01.005
State	Published - Apr 2021

Bibliographical note

Funding Information:
R.C. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include serving on a speaker's bureau for Abbott and on the heart failure advisory board for Medtronic. Her spouse is employed by Medtronic. R.J. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include serving as a consultant to Medtronic and Abbott. L.L. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include an intellectual property with Abbott. B.A.H. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include receiving research funding from Medtronic for work outside this study. R.J.T. reports no direct conflicts relevant to this manuscript. Other general conflicts include consulting relationships with Medtronic, Aria CV Inc., Arena Pharmaceuticals, Acceleron, Eidos Therapeutics, Gradient, and United Therapeutics. R.J.T. is on a steering committee for Medtronic and Abbott as well as a research advisory board for Abiomed. He also does hemodynamic core laboratory work for Actelion and Merck. The remaining authors have no conflicts of interest to disclose.

Publisher Copyright:
© 2021 International Society for Heart and Lung Transplantation

Keywords

INTERMACS
LVAD
mechanical circulatory support
pulmonary hypertension
right heart failure
right ventricle
thoracotomy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.healun.2021.01.005

OpenUrl availability

Full text

Cite this

Saeed, D., Muslem, R., Rasheed, M., Caliskan, K., Kalampokas, N., Sipahi, F., Lichtenberg, A., Jawad, K., Borger, M., Huhn, S., Cogswell, R., John, R., Schultz, J., Shah, H., Hsu, S., Gilotra, N. A., Scheel, P. J., Tomashitis, B., Hajj, M. E., ... Tedford, R. J. (2021). Less invasive surgical implant strategy and right heart failure after LVAD implantation. Journal of Heart and Lung Transplantation, 40(4), 289-297. https://doi.org/10.1016/j.healun.2021.01.005

Saeed, D, Muslem, R, Rasheed, M, Caliskan, K, Kalampokas, N, Sipahi, F, Lichtenberg, A, Jawad, K, Borger, M, Huhn, S, Cogswell, R , John, R , Schultz, J, Shah, H, Hsu, S, Gilotra, NA, Scheel, PJ, Tomashitis, B, Hajj, ME, Lozonschi, L, Houston, BA & Tedford, RJ 2021, 'Less invasive surgical implant strategy and right heart failure after LVAD implantation', Journal of Heart and Lung Transplantation, vol. 40, no. 4, pp. 289-297. https://doi.org/10.1016/j.healun.2021.01.005

@article{c14239fc53a943318ca34bcefd92c643,

title = "Less invasive surgical implant strategy and right heart failure after LVAD implantation",

abstract = "BACKGROUND: Conventional median sternotomy (CMS) is still the standard technique utilized to implant left ventricular assist devices (LVADs). Recent studies suggest that less invasive surgery (LIS) may be beneficial; however, robust data on differences in right heart failure (RHF) are lacking. This study aimed to determine the impact of LIS compared with that of CMS on RHF outcomes after LVAD implantation. METHODS: An international multicenter retrospective cohort study was conducted across 5 centers. Patients were grouped according to their implantation technique (LIS vs CMS). Only centrifugal devices were included. RHF was defined as severe or severe acute RHF according to the 2013 Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definition. Logistic multivariate regression and propensity score‒matched analyses were performed to account for confounding. RESULTS: Overall, 427 implantations occurred during the study period, with 305 patients implanted using CMS and 122 using LIS. Pre-operative extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump (IABP) use was more common in the CMS group; off-pump implantation was more common in the LIS group. Other pre-implant variables, including age, creatinine, hemodynamics, and tricuspid regurgitation, did not differ between the 2 groups. Post-operative RHF was less common in the patients who underwent LIS than in those who underwent CMS as was post-operative right ventricular assist device (RVAD) use. LIS remained associated with less RHF in the multivariate analysis. After propensity score matching conditional for age, sex, INTERMACS profile, ECMO, and IABP use in a ratio of 2:1 (CMS to LIS), RHF (29.9% vs 18.6%, p = 0.001) and the need for post-operative RVAD (18.6% vs 8.2%; p = 0.009) remained more common in the CMS group than in the LIS group. There were no significant differences in survival up to 1 year between the groups. CONCLUSIONS: LIS may be associated with less RHF after LVAD implantation compared with CMS. Despite the possible reduction in RHF, there was no difference in 1-year survival. LIS is an alternative to traditional CMS.",

keywords = "INTERMACS, LVAD, mechanical circulatory support, pulmonary hypertension, right heart failure, right ventricle, thoracotomy",

author = "Diyar Saeed and Rahatullah Muslem and Moniba Rasheed and Kadir Caliskan and Nikolaos Kalampokas and Firat Sipahi and Artur Lichtenberg and Khalil Jawad and Michael Borger and Simone Huhn and Rebecca Cogswell and Ranjit John and Jessica Schultz and Hirak Shah and Steven Hsu and Gilotra, {Nisha A.} and Scheel, {Paul J.} and Brett Tomashitis and Hajj, {Milad El} and Lucian Lozonschi and Houston, {Brian A.} and Tedford, {Ryan J.}",

note = "Funding Information: R.C. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include serving on a speaker's bureau for Abbott and on the heart failure advisory board for Medtronic. Her spouse is employed by Medtronic. R.J. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include serving as a consultant to Medtronic and Abbott. L.L. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include an intellectual property with Abbott. B.A.H. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include receiving research funding from Medtronic for work outside this study. R.J.T. reports no direct conflicts relevant to this manuscript. Other general conflicts include consulting relationships with Medtronic, Aria CV Inc., Arena Pharmaceuticals, Acceleron, Eidos Therapeutics, Gradient, and United Therapeutics. R.J.T. is on a steering committee for Medtronic and Abbott as well as a research advisory board for Abiomed. He also does hemodynamic core laboratory work for Actelion and Merck. The remaining authors have no conflicts of interest to disclose. Publisher Copyright: {\textcopyright} 2021 International Society for Heart and Lung Transplantation",

year = "2021",

month = apr,

doi = "10.1016/j.healun.2021.01.005",

language = "English (US)",

volume = "40",

pages = "289--297",

journal = "Journal of Heart and Lung Transplantation",

issn = "1053-2498",

publisher = "Elsevier USA",

number = "4",

}

TY - JOUR

T1 - Less invasive surgical implant strategy and right heart failure after LVAD implantation

AU - Saeed, Diyar

AU - Muslem, Rahatullah

AU - Rasheed, Moniba

AU - Caliskan, Kadir

AU - Kalampokas, Nikolaos

AU - Sipahi, Firat

AU - Lichtenberg, Artur

AU - Jawad, Khalil

AU - Borger, Michael

AU - Huhn, Simone

AU - Cogswell, Rebecca

AU - John, Ranjit

AU - Schultz, Jessica

AU - Shah, Hirak

AU - Hsu, Steven

AU - Gilotra, Nisha A.

AU - Scheel, Paul J.

AU - Tomashitis, Brett

AU - Hajj, Milad El

AU - Lozonschi, Lucian

AU - Houston, Brian A.

AU - Tedford, Ryan J.

N1 - Funding Information: R.C. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include serving on a speaker's bureau for Abbott and on the heart failure advisory board for Medtronic. Her spouse is employed by Medtronic. R.J. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include serving as a consultant to Medtronic and Abbott. L.L. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include an intellectual property with Abbott. B.A.H. reports no direct conflicts of interest relevant to this manuscript. Other general conflicts include receiving research funding from Medtronic for work outside this study. R.J.T. reports no direct conflicts relevant to this manuscript. Other general conflicts include consulting relationships with Medtronic, Aria CV Inc., Arena Pharmaceuticals, Acceleron, Eidos Therapeutics, Gradient, and United Therapeutics. R.J.T. is on a steering committee for Medtronic and Abbott as well as a research advisory board for Abiomed. He also does hemodynamic core laboratory work for Actelion and Merck. The remaining authors have no conflicts of interest to disclose. Publisher Copyright: © 2021 International Society for Heart and Lung Transplantation

PY - 2021/4

Y1 - 2021/4

N2 - BACKGROUND: Conventional median sternotomy (CMS) is still the standard technique utilized to implant left ventricular assist devices (LVADs). Recent studies suggest that less invasive surgery (LIS) may be beneficial; however, robust data on differences in right heart failure (RHF) are lacking. This study aimed to determine the impact of LIS compared with that of CMS on RHF outcomes after LVAD implantation. METHODS: An international multicenter retrospective cohort study was conducted across 5 centers. Patients were grouped according to their implantation technique (LIS vs CMS). Only centrifugal devices were included. RHF was defined as severe or severe acute RHF according to the 2013 Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definition. Logistic multivariate regression and propensity score‒matched analyses were performed to account for confounding. RESULTS: Overall, 427 implantations occurred during the study period, with 305 patients implanted using CMS and 122 using LIS. Pre-operative extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump (IABP) use was more common in the CMS group; off-pump implantation was more common in the LIS group. Other pre-implant variables, including age, creatinine, hemodynamics, and tricuspid regurgitation, did not differ between the 2 groups. Post-operative RHF was less common in the patients who underwent LIS than in those who underwent CMS as was post-operative right ventricular assist device (RVAD) use. LIS remained associated with less RHF in the multivariate analysis. After propensity score matching conditional for age, sex, INTERMACS profile, ECMO, and IABP use in a ratio of 2:1 (CMS to LIS), RHF (29.9% vs 18.6%, p = 0.001) and the need for post-operative RVAD (18.6% vs 8.2%; p = 0.009) remained more common in the CMS group than in the LIS group. There were no significant differences in survival up to 1 year between the groups. CONCLUSIONS: LIS may be associated with less RHF after LVAD implantation compared with CMS. Despite the possible reduction in RHF, there was no difference in 1-year survival. LIS is an alternative to traditional CMS.

AB - BACKGROUND: Conventional median sternotomy (CMS) is still the standard technique utilized to implant left ventricular assist devices (LVADs). Recent studies suggest that less invasive surgery (LIS) may be beneficial; however, robust data on differences in right heart failure (RHF) are lacking. This study aimed to determine the impact of LIS compared with that of CMS on RHF outcomes after LVAD implantation. METHODS: An international multicenter retrospective cohort study was conducted across 5 centers. Patients were grouped according to their implantation technique (LIS vs CMS). Only centrifugal devices were included. RHF was defined as severe or severe acute RHF according to the 2013 Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definition. Logistic multivariate regression and propensity score‒matched analyses were performed to account for confounding. RESULTS: Overall, 427 implantations occurred during the study period, with 305 patients implanted using CMS and 122 using LIS. Pre-operative extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump (IABP) use was more common in the CMS group; off-pump implantation was more common in the LIS group. Other pre-implant variables, including age, creatinine, hemodynamics, and tricuspid regurgitation, did not differ between the 2 groups. Post-operative RHF was less common in the patients who underwent LIS than in those who underwent CMS as was post-operative right ventricular assist device (RVAD) use. LIS remained associated with less RHF in the multivariate analysis. After propensity score matching conditional for age, sex, INTERMACS profile, ECMO, and IABP use in a ratio of 2:1 (CMS to LIS), RHF (29.9% vs 18.6%, p = 0.001) and the need for post-operative RVAD (18.6% vs 8.2%; p = 0.009) remained more common in the CMS group than in the LIS group. There were no significant differences in survival up to 1 year between the groups. CONCLUSIONS: LIS may be associated with less RHF after LVAD implantation compared with CMS. Despite the possible reduction in RHF, there was no difference in 1-year survival. LIS is an alternative to traditional CMS.

KW - INTERMACS

KW - LVAD

KW - mechanical circulatory support

KW - pulmonary hypertension

KW - right heart failure

KW - right ventricle

KW - thoracotomy

UR - http://www.scopus.com/inward/record.url?scp=85099816557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099816557&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2021.01.005

DO - 10.1016/j.healun.2021.01.005

M3 - Article

C2 - 33509653

AN - SCOPUS:85099816557

SN - 1053-2498

VL - 40

SP - 289

EP - 297

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

IS - 4

ER -

Less invasive surgical implant strategy and right heart failure after LVAD implantation

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this